Drug Profile
RG 2833
Alternative Names: RG-FA; RG2833; RGFP-109Latest Information Update: 22 Jun 2021
Price :
$50
*
At a glance
- Originator The Scripps Research Institute
- Developer Johns Hopkins University; Repligen Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action HDAC1 protein inhibitors; HDAC3 protein inhibitors; Transcription factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Friedreich's ataxia
Highest Development Phases
- Preclinical Diffuse intrinsic pontine glioma
- No development reported Friedreich's ataxia
Most Recent Events
- 11 Apr 2021 Pharmacodynamics data from preclinical trials in Diffuse intrinsic pontine glioma presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 10 Apr 2021 Preclinical trials in Diffuse intrinsic pontine glioma in USA (unspecified route), before April 2021
- 16 Jul 2016 No recent reports of development identified for phase-I development in Friedreich's ataxia in Italy (PO)